Sign In to Follow Application
View All Documents & Correspondence

Process Of Isolating Mesenchymal Stem Cells

Abstract: The present invention provides a process of isolation, proliferation and/or maintenance of mesenchymal stem cells (MSCs).The invention further provides a culture medium for proliferation and/or maintenance of human mesenchymal stem cells in xeno-free conditions.The culture medium provides provided in the present invention proliferates and/or maintains mesenchymal stem cell expansion while maintaining a multipotent phenotype

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
23 April 2007
Publication Number
48/2008
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2017-02-06
Renewal Date

Applicants

STEMPEUTIC RESEARCH PVT LTD
9TH FLOOR, MANIPAL HOSPITAL, AIRPORT ROAD, BANGALORE-560017

Inventors

1. SATISH MAHADEORAO TOTEY
9TH FLOOR, MANIPAL HOSPITAL, AIRPORT ROAD, BANGALORE-560017
2. UDAY KUMAR KOLKUNDKAR
9TH FLOOR, MANIPAL HOSPITAL, AIRPORT ROAD, BANGALORE-560017
3. RAKHI PAL
9TH FLOOR, MANIPAL HOSPITAL, AIRPORT ROAD, BANGALORE-560017
4. MADHIRI HANWATE
9TH FLOOR, MANIPAL HOSPITAL, AIRPORT ROAD, BANGALORE-560017

Specification

I/We Claim:
1. A process of isolation of mesenchymal stem cells (MSC) from a sample, said
process comprising;
a) treating said sample with an antibody against an antigen, wherein said antigen is selected from a group consisting of CD44, CD50, CD54, CD73, CD90, CD 105, CD 106, CD 117, oct 3/4, Actin filament associated protein (AFAP), Frizzled7 (FZD7), DickkopG (DKK3), Protein tyrosine phosphatase receptor F (PTPRF), RAB3B, and Stro-1;
b) obtaining cells expressing said antigen; wherein said cells are mesenchymal stem cells; and
c) culturing said mesenchymal stem cells in a growth medium selected from the group consisting of i) a culture medium comprising a basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; 5-10% fetal bovine serum (FBS), growth factors, 200 mM glutamax and antibiotics; ii) a culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human serum, 200 mM glutamax and antibiotics; iii) a culture medium comprising basal medium selected from the group consisting of KO- DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human plasma, heparin, 200 mM glutamax and antibiotics; and iv) a culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human plasma or human serum or a combination thereof, heparin, 200 mM glutamax and antibiotics.
2. The process as claimed in claim 1, wherein said process further comprises maintaining said mesenchymal stem cells after culturing as in step (c) of claim 1 in a maintenance medium selected from the group consisting of i) a culture medium comprising a basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; 5-10% fetal bovine serum (FBS), growth factors, 200 mM glutamax and antibiotics; ii) a culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human serum, 200 mM glutamax and antibiotics; iii) a culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human plasma, heparin, 200 mM glutamax and antibiotics; and iv) a culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors, human plasma or human serunj or a combination thereof, heparin, 200 mM glutamax and antibiotics;
3. The process as claimed in claim 1 or 2, wherein said sample is selected from the group consisting of bone marrow, corneal epithelial tissue, adipose tissue, umbilical cord, placenta, dental ligament and dental pulp.
4. The process as claimed in claim 1 or 2, wherein said sample is bone marrow.
5. The process as claimed in claim 1 or 2, wherein said sample is corneal epithelial tissue.
6. The process as claimed in claim 1 or 2, wherein said sample is adipose tissue.
7. The process as claimed in claim 1 or 2, wherein said sample is umbilical cord.
8. The process as claimed in claim 1 or 2, wherein said sample is placenta.
9. The process as claimed in claim 1 or 2, wherein said sample is dental ligament.
10. The process as claimed in claim 1 or 2, wherein said sample is dental pulp.
11. The process as claimed in claim 1 or 2, wherein said sample is obtained from human or murine origin.
12. The process as claimed in claim 1 or 2, wherein said growth medium comprises a basal medium KO-DMEM, 5-10% fetal bovine serum (FBS), growth factors, 200 mM glutamax and antibiotics.
13. The process as claimed in claim 1 or 2, wherein said growth factors are selected from the group consisting of platelet derived growth factor (PDGF) 5 to 100 r|g/ml, transforming growth factor-beta (TGF-beta) 5 to 50r)g /ml, keratinocyte growth factor (KGF) 4 to 100r|g/ml, basic Fibroblast growth factor (bFGF) 4 to 80 r)g/ml, Epidermal growth factor (EGF) 5 to 50 r|g/ml and Insulin-like growth factor-I (IGF- I) 5 to 50r|g /ml.
14. The process as claimed in claim 1 or 2, wherein concentration of PDGF 20r|g/ml.
15. The process as claimed in claim 1 or 2, wherein concentration of TGF is 20rig /ml.
16. The process as claimed in claim 1 or 2, wherein concentration of said KGF is a 20r|g /ml. •
17. The process as claimed in claim 1 or 2, wherein concentration of bFGF is 10 rjg/ml.
18. The process as claimed in claim 1 or 2, wherein concentration of EGF is 15 rig/ml.
19. The process as claimed in claim 1 or 2, wherein concentration of IGF-I is 20r(g /ml.
20. The process as claimed in claim 1 or 2, wherein concentration of human serum is in the range of 0.5 to 1% (w/w).
21. The process as claimed in claim 1 or 2, wherein concentration of human plasma is in the range of 1 to 20 %(w/w).
22. The process as claimed in claim 1 or 2, wherein concentration of glutamax is 200 mM.
23. The process as claimed in claim 1 or 2, wherein concentration of heparin is in the range of 1000 tolO, 000 U/ml.
24. The process as claimed in claim 1 or 2, wherein said MSCs are negative for a marker selected from the group consisting of CD3, CD4, CD8, CD10, CD13, CD14, CD19, CD29, CD31, CD34, CD36, CD38, CD45, CD62E, CD66b, CD133, HLA I and II, HLA-DR, glycophorin-A, Mucl8, cKit, Tie/Tek, microglobulin, oct 4, Nanog, Rex- 1, TDGF, TERT, SOX-2 and beta actin control.
25. The process as claimed in claim 1 or 2, wherein said mesenchymal stem cells retain the functional characteristics without any abnormalities upto more than 30 passages.
26. The process as claimed in claim 1 or 2, wherein said mesenchymal stem cells retain the fiinctional characteristics without any abnormalities upto 30 passages.
27. The process as claimed in claim 1 or 2, wherein said mesenchymal stem cells are capable of differentiation into cells selected from a group consisting of cardiac cells, neuronal cells, hepatocytes, pancreatic beta cells, osteoblasts, chondrocytes and adipocytes.
28. A cell culture medium for proliferation and/or maintenance of mesenchymal stem cells (MSCs), wherein said culture medium comprising KO-DMEM; growth factors selected from the group consisting of 5 to lOOrjg/ml platelet derived growth factor (PDGF), 5 to 50r|g /ml transforming growth factor-beta (TGF-beta), 4 to 100r)g/ml keratinocyte growth factor (KGF), 4 to 80 r^g/ml basic Fibroblast growth factor (bFGF), 5 to 50 ng/ml Epidermal growth factor (EGF) and 5 to 50rig /ml Insulin-like growth factor-I (IGF-I); 5 to 10% (w/w) fetal bovine serum (FBS); 200 mM glutamax; and antibiotics.
29. A cell culture medium for proliferation and/or maintenance of mesenchymal stem cells (MSCs), wherein said culture medium comprising KO-DMEM; growth factors selected from the group consisting of 5 to 100rig/ml platelet derived growth factor (PDGF), 5 to 50r|g /ml transforming growth factor-beta (TGF-beta), 4 to 100Tig/ml keratinocyte growth factor (KGF), 4 to 80 rig/ml basic Fibroblast growth factor (bFGF), 5 to 50 r|g/ml Epidermal growth factor (EGF) and 5 to 50r|g /ml Insulin-like growth factor-I (IGF-I);human plasma or human serum or a combination thereof; 200 mM glutamax; and antibiotics.
30. A cell culture medium for proliferation and/or maintenance of mesenchymal stem cells (MSCs), wherein said culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors selected from the group consisting of 5 to 100 rig/ml platelet derived growth factor (PDGF), 5 to 50Tig/ml transforming growth factor-beta (TGF-beta), 4 to I00r|g/mi keratinocyte growth factor (KGF), 4 to 80 rig/ml basic Fibroblast growth factor (bFGF), 5 to 50 rig/ml Epidermal growth factor (EGF) and 5 to 50rig/ml Insulin-like growth factor-I (IGF-I); 0.5 to 1% human serum; 200 mM glutamax; and antibiotics.
31. A cell culture medium for proliferation and/or maintenance of mesenchymal stem cells (MSCs), wherein said culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors selected from the group consisting of 5 to 100 rig/ml platelet derived growth factor (PDGF), 5 to 50rig/ml transforming growth factor-beta (TGF-beta), 4 to 100r)g/ml keratinocyte growth factor (KGF), 4 to 80 r|g/m! basic Fibroblast growth factor (bFGF), 5 to 50 r|g/ml Epidermal growth factor (EGF) and 5 to 50rig/ml Insulin-like growth factor-I (IGF-I); 1 to 20 % human plasma; 200 mM glutamax; 1000 to 10,000 U/ml heparin and antibiotics.
32. A cell culture medium for proliferation and/or maintenance of mesenchymal stem cells (MSCs), wherein said culture medium comprising basal medium selected from the group consisting of KO-DMEM, DMEM-LG and DMEM-F12 (1:1) or a combination thereof; growth factors selected from the group consisting of 5 to 100 rig/ml platelet derived growth factor (PDGF), 5 to 50rig/ml transforming growth factor-beta (TGF-beta), 4 to 100rig/ml keratinocyte growth factor (KGF), 4 to 80 rig/ml basic Fibroblast growth factor (bFGF), 5 to 50 rig/ml Epidermal growth factor (EGF) and 5 to 50iig/ml Insulin-like growth factor-I (IGF-I); 0.5 to 1% human serum or 1 to 20 % human plasma; 200 mM glutamax; 1000 to 10,000 U/ml heparin and antibiotics. ^

Documents

Orders

Section Controller Decision Date
u/s 15 Dr. Bhanumathi R. 2017-02-06
u/s 15 Dr. Bhanumathi R. 2017-02-06
u/s 15 Dr. Bhanumathi R. 2017-02-06

Application Documents

# Name Date
1 861-CHE-2007 FORM-18 02-12-2009.pdf 2009-12-02
1 861-CHE-2007-FORM 4 [02-05-2024(online)].pdf 2024-05-02
2 861-che-2007 correspondence others 10-02-2011.pdf 2011-02-10
2 861-CHE-2007-FORM 4 [04-05-2023(online)].pdf 2023-05-04
3 861-CHE-2007-EVIDENCE FOR REGISTRATION UNDER SSI [03-05-2023(online)].pdf 2023-05-03
3 861-che-2007 form-3 10-02-2011.pdf 2011-02-10
4 861-CHE-2007-FORM FOR SMALL ENTITY [03-05-2023(online)].pdf 2023-05-03
4 861-che-2007-form 5.pdf 2011-09-03
5 861-CHE-2007-FORM FOR SMALL ENTITY [22-04-2021(online)].pdf 2021-04-22
5 861-che-2007-form 3.pdf 2011-09-03
6 861-CHE-2007-RELEVANT DOCUMENTS [16-03-2020(online)].pdf 2020-03-16
6 861-che-2007-form 1.pdf 2011-09-03
7 Correspondence by Applicant_Fee Payment_12-04-2019.pdf 2019-04-12
7 861-che-2007-description(provisional).pdf 2011-09-03
8 861-CHE-2007-RELEVANT DOCUMENTS [15-03-2019(online)].pdf 2019-03-15
8 861-che-2007-correspondnece-others.pdf 2011-09-03
9 861-CHE-2007 POWER OF ATTORNEY.pdf 2012-03-12
9 861-CHE-2007-RELEVANT DOCUMENTS [22-02-2018(online)].pdf 2018-02-22
10 861-CHE-2007 DRAWINGS.pdf 2012-03-12
10 EVIDENCE FOR SSI [04-05-2017(online)].pdf 2017-05-04
11 861-CHE-2007 CORRESPONDENCE PO.pdf 2012-03-12
11 FORM28 [04-05-2017(online)].pdf 2017-05-04
12 861-CHE-2007 CLAIMS.pdf 2012-03-12
12 EVIDENCE FOR SSI [28-04-2017(online)].pdf 2017-04-28
13 861-CHE-2007 ABSTRACT.pdf 2012-03-12
13 FORM28 [28-04-2017(online)].pdf 2017-04-28
14 861-CHE-2007 CORRESPONDENCE OTHERS 05-10-2012.pdf 2012-10-05
14 Abstract_Granted 279948_06-02-2017.pdf 2017-02-06
15 861-CHE-2007 POWER OF ATTORNEY 05-10-2012.pdf 2012-10-05
15 Claims_Granted 279948_06-02-2017.pdf 2017-02-06
16 861-CHE-2007 FORM-13-1 05-10-2012.pdf 2012-10-05
16 Drawings_Granted 279948_06-02-2017.pdf 2017-02-06
17 Marked Up Claims_Granted 279948_06-02-2017.pdf 2017-02-06
17 861-CHE-2007 FORM-13 05-10-2012.pdf 2012-10-05
18 861-CHE-2007 FORM-1 05-10-2012.pdf 2012-10-05
18 Other Patent Document [02-02-2017(online)].pdf 2017-02-02
19 861-CHE-2007 FORM-3 27-03-2014.pdf 2014-03-27
19 Other Patent Document [19-01-2017(online)].pdf 2017-01-19
20 861-CHE-2007 CORRESPONDENCE OTHERS 27-03-2014.pdf 2014-03-27
20 861-CHE-2007_EXAMREPORT.pdf 2016-07-02
21 Abstract - Marked & Clear version .pdf 2014-10-07
21 Form 28.pdf 2014-04-15
22 Certificate from DIC, Govt of Karnataka.pdf 2014-04-15
22 Claims- Marked & Clear version.pdf 2014-10-07
23 861-CHE-2007 FORM-13 22-04-2014.pdf 2014-04-22
23 Complete Specification.pdf 2014-10-07
24 MSME Certificate.pdf 2014-10-07
24 861-CHE-2007 OTHER PATENT DOCUMENT 22-04-2014.pdf 2014-04-22
25 Non-Final Office Action 24.04.2014.pdf 2014-10-07
25 PETITION UNDER RULE 137 - for irregularity in submission of Form 3.pdf 2014-04-23
26 FORM 13.pdf 2014-04-23
26 Response to SER.pdf 2014-10-07
27 861-CHE-2007 AMENDED CLAIMS 23-04-2014.pdf 2014-04-23
27 Amended FORM 1-IP21464.pdf 2014-04-23
28 861-CHE-2007 FORM-1 23-04-2014.pdf 2014-04-23
28 861-CHENP-2007 EXAMINATION REPORT REPLY RECEIVED 23-04-2014.pdf 2014-04-23
29 861-CHE-2007 POWER OF ATTORNEY 23-04-2014.pdf 2014-04-23
30 861-CHE-2007 FORM-1 23-04-2014.pdf 2014-04-23
30 861-CHENP-2007 EXAMINATION REPORT REPLY RECEIVED 23-04-2014.pdf 2014-04-23
31 861-CHE-2007 AMENDED CLAIMS 23-04-2014.pdf 2014-04-23
31 Amended FORM 1-IP21464.pdf 2014-04-23
32 FORM 13.pdf 2014-04-23
32 Response to SER.pdf 2014-10-07
33 Non-Final Office Action 24.04.2014.pdf 2014-10-07
33 PETITION UNDER RULE 137 - for irregularity in submission of Form 3.pdf 2014-04-23
34 861-CHE-2007 OTHER PATENT DOCUMENT 22-04-2014.pdf 2014-04-22
34 MSME Certificate.pdf 2014-10-07
35 861-CHE-2007 FORM-13 22-04-2014.pdf 2014-04-22
35 Complete Specification.pdf 2014-10-07
36 Claims- Marked & Clear version.pdf 2014-10-07
36 Certificate from DIC, Govt of Karnataka.pdf 2014-04-15
37 Form 28.pdf 2014-04-15
37 Abstract - Marked & Clear version .pdf 2014-10-07
38 861-CHE-2007 CORRESPONDENCE OTHERS 27-03-2014.pdf 2014-03-27
38 861-CHE-2007_EXAMREPORT.pdf 2016-07-02
39 861-CHE-2007 FORM-3 27-03-2014.pdf 2014-03-27
39 Other Patent Document [19-01-2017(online)].pdf 2017-01-19
40 861-CHE-2007 FORM-1 05-10-2012.pdf 2012-10-05
40 Other Patent Document [02-02-2017(online)].pdf 2017-02-02
41 861-CHE-2007 FORM-13 05-10-2012.pdf 2012-10-05
41 Marked Up Claims_Granted 279948_06-02-2017.pdf 2017-02-06
42 861-CHE-2007 FORM-13-1 05-10-2012.pdf 2012-10-05
42 Drawings_Granted 279948_06-02-2017.pdf 2017-02-06
43 861-CHE-2007 POWER OF ATTORNEY 05-10-2012.pdf 2012-10-05
43 Claims_Granted 279948_06-02-2017.pdf 2017-02-06
44 861-CHE-2007 CORRESPONDENCE OTHERS 05-10-2012.pdf 2012-10-05
44 Abstract_Granted 279948_06-02-2017.pdf 2017-02-06
45 861-CHE-2007 ABSTRACT.pdf 2012-03-12
45 FORM28 [28-04-2017(online)].pdf 2017-04-28
46 EVIDENCE FOR SSI [28-04-2017(online)].pdf 2017-04-28
46 861-CHE-2007 CLAIMS.pdf 2012-03-12
47 861-CHE-2007 CORRESPONDENCE PO.pdf 2012-03-12
47 FORM28 [04-05-2017(online)].pdf 2017-05-04
48 861-CHE-2007 DRAWINGS.pdf 2012-03-12
48 EVIDENCE FOR SSI [04-05-2017(online)].pdf 2017-05-04
49 861-CHE-2007 POWER OF ATTORNEY.pdf 2012-03-12
49 861-CHE-2007-RELEVANT DOCUMENTS [22-02-2018(online)].pdf 2018-02-22
50 861-che-2007-correspondnece-others.pdf 2011-09-03
50 861-CHE-2007-RELEVANT DOCUMENTS [15-03-2019(online)].pdf 2019-03-15
51 861-che-2007-description(provisional).pdf 2011-09-03
51 Correspondence by Applicant_Fee Payment_12-04-2019.pdf 2019-04-12
52 861-che-2007-form 1.pdf 2011-09-03
52 861-CHE-2007-RELEVANT DOCUMENTS [16-03-2020(online)].pdf 2020-03-16
53 861-che-2007-form 3.pdf 2011-09-03
53 861-CHE-2007-FORM FOR SMALL ENTITY [22-04-2021(online)].pdf 2021-04-22
54 861-CHE-2007-FORM FOR SMALL ENTITY [03-05-2023(online)].pdf 2023-05-03
54 861-che-2007-form 5.pdf 2011-09-03
55 861-CHE-2007-EVIDENCE FOR REGISTRATION UNDER SSI [03-05-2023(online)].pdf 2023-05-03
55 861-che-2007 form-3 10-02-2011.pdf 2011-02-10
56 861-CHE-2007-FORM 4 [04-05-2023(online)].pdf 2023-05-04
57 861-CHE-2007-FORM 4 [02-05-2024(online)].pdf 2024-05-02
58 861-CHE-2007-FORM 4 [22-07-2025(online)].pdf 2025-07-22
59 861-CHE-2007-FORM-15 [31-10-2025(online)].pdf 2025-10-31
60 861-CHE-2007-FORM 4 [31-10-2025(online)].pdf 2025-10-31
61 861-CHE-2007-FORM 4 [31-10-2025(online)]-1.pdf 2025-10-31
62 861-CHE-2007-FORM-26 [13-11-2025(online)].pdf 2025-11-13
63 861-CHE-2007-POA [20-11-2025(online)].pdf 2025-11-20
64 861-CHE-2007-FORM 13 [20-11-2025(online)].pdf 2025-11-20

ERegister / Renewals

3rd: 28 Apr 2017

From 23/04/2009 - To 23/04/2010

4th: 28 Apr 2017

From 23/04/2010 - To 23/04/2011

5th: 28 Apr 2017

From 23/04/2011 - To 23/04/2012

6th: 28 Apr 2017

From 23/04/2012 - To 23/04/2013

7th: 28 Apr 2017

From 23/04/2013 - To 23/04/2014

8th: 28 Apr 2017

From 23/04/2014 - To 23/04/2015

9th: 28 Apr 2017

From 23/04/2015 - To 23/04/2016

10th: 28 Apr 2017

From 23/04/2016 - To 23/04/2017

11th: 04 May 2017

From 23/04/2017 - To 23/04/2018

12th: 23 Apr 2018

From 23/04/2018 - To 23/04/2019

13th: 12 Apr 2019

From 23/04/2019 - To 23/04/2020

14th: 15 Apr 2020

From 23/04/2020 - To 23/04/2021

15th: 22 Apr 2021

From 23/04/2021 - To 23/04/2022

16th: 22 Apr 2021

From 23/04/2022 - To 23/04/2023

17th: 04 May 2023

From 23/04/2023 - To 23/04/2024

18th: 02 May 2024

From 23/04/2024 - To 23/04/2025